You are here
Sunday, January 11, 2009
Researchers Identify New Regulatory Circuit Controlling Immune Cell Production in Mice
Using a mouse model, researchers have shown that elevated levels of a small protein known as interleukin 7 (IL-7) plays a central role in regulating the production of a type of white blood cell that is required for effective immune responses. This finding helps explain the delayed and incomplete recovery of immune system function after treatments such as chemotherapy and bone marrow transplantation, in which immune cells are destroyed, and provides insight into the mechanism by which certain types of immune cells are depleted during HIV infection. The study, by researchers at the National Cancer Institute (NCI), the National Institute of Diabetes, Digestive, and Kidney Diseases, and the National Institute of Allergy and Infectious Diseases, parts of the National Institutes of Health (NIH), appeared online Jan. 11, 2009, in Nature Immunology.
White blood cells known as T lymphocytes, or T cells, are essential components of the immune system. They can be divided into two major groups: CD4+ T cells, which act as helper cells, directing the activity of other immune cells, and CD8+ T cells, which kill infected cells and tumor cells. The function of the thymus, the organ where T cells differentiate in order to perform specific functions, declines with age. When T cells become depleted in adults, they can undergo spontaneous, or homeostatic, proliferation in an attempt to restore their numbers. Although homeostatic proliferation efficiently regenerates CD8+ T cells, it is much less efficient in regenerating CD4+ T cells.
"Essentially any clinical condition that induces the death of lymphocytes is followed by restoration of CD8+ T cells with chronic long-term deficiency of CD4+ T cells," said study author Crystal Mackall, M.D., of NCI's Center for Cancer Research. "For example, after bone marrow transplantation, patients recover essentially every other type of lymphocyte within six to eight months but the depletion of CD4+ T cells can last years."
Indeed, although CD4+ T cell depletion is the main hallmark of HIV infection, it has remained an enigma why CD8+ T cells are not similarly depleted, given that both CD4+ and CD8+ T cells are killed during the course of the disease. Because CD4+ T cells are the initiators of adaptive immunity, which enables the immune system to recognize and remember pathogens, normal immune system functioning cannot be restored unless CD4+ T cell numbers recover.
IL-7 is a cytokine that is known to play an important role in homeostatic proliferation of T cells. Cytokines are small proteins produced by immune cells that help regulate immune responses. When the level of lymphocytes in the blood is low — a condition known as lymphopenia — concentrations of IL-7 increase. Previous research in humans has indicated that, despite IL-7's role in stimulating homeostatic T cell proliferation, elevated levels of IL-7 may be associated with low CD4+ T cell counts.
To investigate the role of IL-7 in CD4+ T cell homeostasis, the researchers injected T cells labeled with a marker into mice depleted of lymphocytes, and, in a subset of these mice, they also administered laboratory-produced IL-7 to further increase the level of IL-7 in the blood. Using flow cytometry, a laboratory technique that allows researchers to measure the concentrations of different types of cells, they found that, within seven days, most of the CD8+ T cells had divided, but the proliferation of CD4+ T cells was minimal.
Dendritic cells are a specialized type of white blood cells that can potently induce T cell activation, and some of these cells contain cell surface proteins that act as receptors for IL-7. Mackall's team also found that interruption of IL-7-induced signaling in these dendritic cells led to an increase in CD4+ T cell proliferation. Cell signaling is a biochemical pathway that regulates cellular functions, such as proliferation or survival. The researchers say that this finding identifies a new regulatory circuit that prevents uncontrolled CD4+ T cell proliferation in mice.
"This work in mice may provide an answer to a clinical problem that has been recognized for some time, but has had no reasonable mechanistic basis for understanding," said Mackall. "It also points out the intricacies of regulatory biology in general and IL-7 biology in particular, since IL-7 has not previously been implicated in turning off immune reactions, but rather serving as an immune stimulant. This work provides a counterpoint to considering IL-7 solely as an immune stimulator."
For more information on Dr. Mackall's research, please go to http://ccr.cancer.gov/staff/staff.asp?profileid=5595.
NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®